Published in Bioorg Med Chem Lett on September 10, 2009
Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral Fragments. ACS Comb Sci (2016) 0.78
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst (2007) 4.14
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.13
Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy. Radiology (2012) 2.36
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst (2005) 2.09
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol (2006) 1.66
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. Bioorg Med Chem (2010) 1.40
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One (2009) 1.30
Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes. Annu Rev Physiol (2005) 1.27
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood (2012) 1.23
Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2010) 1.22
Retracted Autoimmunity as the consequence of a spontaneous mutation in Rasgrp1. Immunity (2003) 1.15
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol (2006) 1.14
Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets (2013) 1.12
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem (2012) 1.11
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother (2012) 1.06
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. J Natl Cancer Inst (2011) 1.05
Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal (2012) 1.04
Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res (2005) 1.03
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist (2009) 1.02
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer (2011) 1.02
Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr Pharm Des (2013) 1.01
The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts. FASEB J (2011) 1.01
Dose and outcome: the hurdle of neutropenia (Review). Oncol Rep (2006) 1.00
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. J Thorac Oncol (2015) 0.99
Organosulfur compounds: electrophilic reagents in transition-metal-catalyzed carbon-carbon bond-forming reactions. Angew Chem Int Ed Engl (2005) 0.99
Autophagy in blood cancers: biological role and therapeutic implications. Haematologica (2013) 0.99
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist (2008) 0.97
Recent synthetic approaches toward non-anomeric spiroketals in natural products. Molecules (2008) 0.97
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res Treat (2013) 0.97
IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J Cancer (2009) 0.96
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. Clinicoecon Outcomes Res (2012) 0.96
NAD+ levels control Ca2+ store replenishment and mitogen-induced increase of cytosolic Ca2+ by Cyclic ADP-ribose-dependent TRPM2 channel gating in human T lymphocytes. J Biol Chem (2012) 0.96
Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother (2013) 0.96
Conformational selection in substrate recognition by Hsp70 chaperones. J Mol Biol (2012) 0.96
Gender-related difference in ST-elevation myocardial infarction treated with primary angioplasty: a single-centre 6-year registry. Eur J Prev Cardiol (2011) 0.95
Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin Cancer Res (2004) 0.94
Silyl methallylsulfinates: efficient and powerful agents for the chemoselective silylation of alcohols, polyols, phenols and carboxylic acids. Chem Commun (Camb) (2005) 0.93
Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. J Thorac Oncol (2011) 0.93
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. Blood (2013) 0.93
Calciphylaxis in a patient with POEMS syndrome without renal failure and/or hyperparathyroidism. A case report. Ann Ital Med Int (2005) 0.92
Ras-induced resistance to lapatinib is overcome by MEK inhibition. Curr Cancer Drug Targets (2010) 0.92
Structural insights into the specificity of Xyn10B from Paenibacillus barcinonensis and its improved stability by forced protein evolution. J Biol Chem (2009) 0.91
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcomes Res (2013) 0.91
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One (2011) 0.90
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Target Oncol (2014) 0.90
Synthesis of the C(1)-C(11) polyene fragment of apoptolidin with a new sulfur dioxide-based organic chemistry. Chemistry (2005) 0.90
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. J Thorac Oncol (2007) 0.89
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer (2008) 0.89
Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev (2007) 0.89
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One (2009) 0.89
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. Leuk Res (2010) 0.89
Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. Int J Cancer (2008) 0.89
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin Hematol (2012) 0.88
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp Hematol (2010) 0.88
Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells. Autophagy (2013) 0.87
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer (2008) 0.87
Discovery of novel and selective SIRT6 inhibitors. J Med Chem (2014) 0.87
The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer. World J Surg Oncol (2013) 0.86
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. J Thorac Oncol (2015) 0.86
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors. Oncologist (2010) 0.85
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. Expert Rev Anticancer Ther (2012) 0.85
Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome. Mediators Inflamm (2013) 0.85
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PLoS One (2010) 0.85
Synthesis of novel pyrrolidine 3,4-diol derivatives as inhibitors of alpha-L-fucosidases. Org Biomol Chem (2009) 0.85
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. Lung Cancer (2010) 0.85
New efficient route to an advanced precursor of the AB spiroketal of spongistatins. Org Lett (2007) 0.85
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. J Med Chem (2012) 0.85
APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood (2009) 0.85
Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane. J Pharmacol Exp Ther (2009) 0.85
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol (2008) 0.84
The vulnerable coronary plaque: update on imaging technologies. Thromb Haemost (2013) 0.84
New synthetic seven-membered 1-azasugars displaying potent inhibition towards glycosidases and glucosylceramide transferase. Chembiochem (2008) 0.84
CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. J Biol Chem (2013) 0.84
Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. Thromb Haemost (2014) 0.84
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. J Thorac Oncol (2014) 0.84
Scope and limitations of the double [4+3]-cycloadditions of 2-oxyallyl cations to 2,2'-methylenedifuran and derivatives. J Org Chem (2003) 0.84